CD4 and type 1 diabetes mellitus: Based on these previous studies, we hypothesized that use of the glycolysis inhibitor PFK15 would inhibit the activation, proliferation, and effector capabilities of autoreactive CD4+ T cells, thereby delaying the onset of T1D.